Biocept Shares Add 6%

Biocept shares were higher 6% as the company said the Columbia University Medical Center will conduct a study to evaluate the clinical utility of Biocept’s Target Selector liquid biopsy technology to diagnose leptomeningeal metastases (LM) in patients with breast cancer.

Biocept’s liquid biopsy platform will be used to test the CSF of breast cancer patients and will be compared to standard methods for confirming the diagnosis of LM. The clinical trial is expected to enroll 46 patients with breast cancer who are undergoing lumbar puncture to detect the presence of LM.

Leave a Comment